Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITDAEPS (Basic)EPS (Weighted Average and Diluted)Income towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Summit Therapeutics (SMMT) Income from Continuing Operations (2022 - 2024)

Summit Therapeutics' Income from Continuing Operations history spans 3 years, with the latest figure at 65623000.0 for Q4 2024.

  • For Q4 2024, Income from Continuing Operations fell 81.23% year-over-year to 65623000.0; the TTM value through Dec 2024 reached 234684000.0, up 61.51%, while the annual FY2024 figure was 234684000.0, 61.84% up from the prior year.
  • Income from Continuing Operations reached 65623000.0 in Q4 2024 per SMMT's latest filing, down from 60832000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 15794000.0 in Q2 2023 to a low of 537154000.0 in Q1 2023.
  • Average Income from Continuing Operations over 3 years is 88157300.0, with a median of 40860000.0 recorded in 2023.
  • The largest YoY upside for Income from Continuing Operations was 91.53% in 2024 against a maximum downside of 297.11% in 2024.
  • A 3-year view of Income from Continuing Operations shows it stood at 20299000.0 in 2022, then tumbled by 78.38% to 36210000.0 in 2023, then tumbled by 81.23% to 65623000.0 in 2024.
  • Per Business Quant, the three most recent readings for SMMT's Income from Continuing Operations are 65623000.0 (Q4 2024), 60832000.0 (Q3 2024), and 62719000.0 (Q2 2024).